Instead of quashing mergers and acquisitions altogether, the U.S. Treasury Dept.'s proposal on tax inversions may pull dealmaking onshore.
(Reuters) - Investors and bankers have been lamenting the potential death of large cross-border healthcare mergers since the U.S. Treasury Dept. announced in late September that it would curtail the tax breaks from international deals designed to give U.S. companies a legal home in a low-tax country.
Atherectomy and balloon angioplasty proves more effective than angioplasty alone in treating peripheral artery disease, according to new data from a Covidien study.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic unveils post-merger management structure; Abbott buys into electrophysiology with $250m Topera acquisition; Zimmer reveals post-Biomet merger plans; Medtronic, Covidien merger expected to close in 2015; Covidien deals Stellarex balloon to Spectranetics for $30m
Covidien's fiscal 4th-quarter and 2014 earnings top expectations on Wall Street as 4th-quarter profits soar 39%.
Covidien (NYSE:COV) handily beat analysts' expectations for its fiscal 4th-quarter and full-year results this morning, topping earnings-per-share forecasts with Q4 profit growth of 39%.
Covidien says the FDA granted 510(k) clearance for its HawkOne atherectomy device.
Covidien agrees to deal its Stellarex drug-coated balloon to Spectranetics for $30 million is it looks to satisfy U.S. anti-trust regulators ahead of a $43 billion merger with Medtronic.
Medtronic CEO Omar Ishrak unveils the plan for the medical device giant's management structure after it closes its mega-merger with Covidien early next year.